Real-life reliability of plasma pTau181, Aβ 42 /Aβ 40 , and pTau181/Aβ 42 measured by Lumipulse G600II in predicting cerebrospinal fluid amyloid status
Journal of Alzheimer’s Disease · 2025
DOI: 10.1177/13872877241300315 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2025. Verfasst von Daniele Imperiale und 19 weiteren Autor:innen. Beteiligte Einrichtung: SC Neurologia, Ospedale Maria Vittoria, Torino, Italy. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, tau Proteins, Alzheimer Disease, Peptide Fragments. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
Alzheimer's disease (AD) is the most common neurodegenerative dementia, with diagnosis traditionally reliant on clinical criteria. Cerebrospinal fluid (CSF) biomarkers like pTau181 and Aβ 42 /Aβ 40 ratio significantly improve diagnostic accuracy but are invasive. Plasma biomarkers measured by automated assays offer a non-invasive alternative.
Objective
To evaluate the diagnostic performance of plasma pTau181, Aβ 42 /Aβ 40 , and pTau181/Aβ 42 ratios in predicting CSF amyloid status in a real-life clinical setting.
Methods
Data from consecutive patients whose plasma and CSF samples sent to our laboratory between March and October 2022, were retrospectively analyzed. Plasma and CSF pTau181, Aβ 42 , and Aβ 40 levels were measured using the Lumipulse G600II platform. CSF amyloid status was classified as amyloid-positive (A+) or amyloid-negative (A-) based on the Aβ 42 /Aβ 40 ratio. Statistical analyses included Spearman correlation, receiver operating characteristic (ROC) curves, and multivariate logistic regression to evaluate biomarker performance.
Results
Among 165 individuals (83 females), 29.1% were classified as A+. Significant correlations were found between plasma and CSF biomarkers, with the highest for the pTau181/Aβ 42 ratio (ρ=0.620, p < 0.0001). ROC analysis showed the pTau181/Aβ 42 ratio had the highest diagnostic performance (AUC 0.818), followed by pTau181 (AUC 0.794) and Aβ 42 /Aβ 40 (AUC 0.775). Combining plasma biomarkers in age-adjusted models improved diagnostic accuracy (AUC up to 0.846).
Conclusions
Plasma biomarkers measured by the Lumipulse G600II platform show strong potential in predicting CSF amyloid status and possibly reduces the need for lumbar punctures. These findings support the potential use of plasma assays in the early diagnosis of AD. Anyway, further validations in larger multicenter cohorts are mandatory.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- SC Neurologia, Ospedale Maria Vittoria, Torino, Italy.
- Centro regionale Diagnosi Osservazione Malattie Prioniche - Laboratorio di Neurobiologia, Ospedale Maria Vittoria, Torino, Italy.
- SCDU Malattie Infettive, Dipartimento di Scienze Mediche - Università di Torino, Ospedale Amedeo di Savoia, Torino, Italy.
- SC Neurologia, A.O. S. Croce e Carle, Cuneo, Italy.
- SC Neurologia, Nuovo Ospedale degli Infermi, Biella, Italy.
- SC Neurologia, Ospedale San Giacomo, Novi Ligure, Italy.
ORCID-Profile: Daniele Imperiale
Zitieren
APA
Imperiale, D., Atzori, C., Angeloro, D. P., Murgioni, A., Bagatin, A., Secci, V., Calcagno, A., Capobianco, M., Coletti Moja, M., Rota, E., Bongioanni, M. R., Rosso, M., Godi, L., Barra, M., De Mattei, M., Bonzanino, M., Ferrandi, D., Rainero, I., Lopiano, L., & Bozzali, M. (2025). Real-life reliability of plasma pTau181, Aβ 42 /Aβ 40 , and pTau181/Aβ 42 measured by Lumipulse G600II in predicting cerebrospinal fluid amyloid status. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877241300315
Vancouver
Imperiale D, Atzori C, Angeloro DP, Murgioni A, Bagatin A, Secci V, et al. Real-life reliability of plasma pTau181, Aβ 42 /Aβ 40 , and pTau181/Aβ 42 measured by Lumipulse G600II in predicting cerebrospinal fluid amyloid status. Journal of Alzheimer’s Disease. 2025. doi:10.1177/13872877241300315
BibTeX
@article{Imperiale2025,
author = {Imperiale, Daniele and Atzori, Cristiana and Angeloro, Daniele Pio and Murgioni, Amelia and Bagatin, Alessia and Secci, Valentina and Calcagno, Andrea and Capobianco, Marco and Coletti Moja, Mario and Rota, Eugenia and Bongioanni, Maria Roberta and Rosso, Mara and Godi, Laura and Barra, Massimo and De Mattei, Marco and Bonzanino, Massimo and Ferrandi, Delfina and Rainero, Innocenzo and Lopiano, Leonardo and Bozzali, Marco},
title = {Real-life reliability of plasma pTau181, Aβ 42 /Aβ 40 , and pTau181/Aβ 42 measured by Lumipulse G600II in predicting cerebrospinal fluid amyloid status},
journal = {Journal of Alzheimer’s Disease},
year = {2025},
doi = {10.1177/13872877241300315}
}
EUVIMED